MiNK-PRAME-TCR / MiNK Therapeutics - LARVOL DELTA

PRAME-TCR iNKT Represents a Promising Targeted Therapy for Refractory Solid Tumors (GlobeNewswire) - "In preclinical studies, PRAME-TCR-iNKTs direct tumor cell killing with high specificity, which highlights the versatility of iNKT cells and their potential of to treat solid tumors such as NSCLC, ovarian, melanoma and sarcoma."

Preclinical • Melanoma • Non Small Cell Lung Cancer • Ovarian Cancer • Sarcoma

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024 (GlobeNewswire) - "MiNK Therapeutics, Inc...announced two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 29th Annual Meeting on November 6-10, 2024, in Houston, Texas. The presentations will showcase new preclinical data from MiNK’s iNKT cell programs, agenT-797 and PRAME-TCR."

Preclinical • Oncology • Solid Tumor